Is PT-141 FDA Approved? The Bremelanotide Story

The Short Answer

Yes and no. The molecule itself, bremelanotide, is FDA-approved. The branded product Vyleesi was approved in June 2019 for a specific indication: hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first and only FDA-approved treatment that targets sexual desire through the central nervous system.

Compounded PT-141 contains the same active molecule but is prescribed off-label for broader applications: sexual health in men, post-menopausal women, and indications beyond the narrow FDA-approved use. This is standard medical practice. Off-label prescribing accounts for roughly 20% of all prescriptions in the United States.

Vyleesi: The FDA-Approved Product

Vyleesi was developed by Palatin Technologies, a New Jersey pharmaceutical company that spent over 15 years bringing bremelanotide through clinical development. The FDA approval was based on two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) enrolling over 1,200 premenopausal women diagnosed with HSDD.

The trials measured sexual desire using the Female Sexual Distress Scale (FSDS-R) and the Female Sexual Function Index (FSFI). Results showed statistically significant improvements in desire and reductions in distress compared to placebo. The most common side effects were nausea (40% of patients), flushing, and injection site reactions. Nausea was typically mild and decreased with repeated use.

How PT-141 Works: Brain, Not Blood Flow

PT-141 works through a fundamentally different mechanism than Viagra, Cialis, or any PDE5 inhibitor. Those drugs increase blood flow to the genitals by inhibiting phosphodiesterase-5. They address the mechanics of erection or arousal but do not affect desire itself.

PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, a region of the brain that regulates sexual desire and arousal at the neurological level. The melanocortin system is part of the brain's reward and motivation circuitry. By stimulating MC4R, PT-141 increases sexual desire and arousal from the top down, starting in the brain rather than the vasculature.

Compounded PT-141: Off-Label Use

The FDA-approved indication for Vyleesi is narrow: HSDD in premenopausal women. But the melanocortin system operates the same way in men and post-menopausal women. Compounded PT-141 is the same bremelanotide molecule, prescribed off-label for:

Men with erectile dysfunction. PT-141 targets desire and arousal through the brain, making it effective for men who do not respond well to PDE5 inhibitors or whose ED has a psychological component. It works through a completely different pathway.

Men with low libido. Testosterone is not the only driver of male sexual desire. The melanocortin system plays a significant role, and PT-141 directly stimulates this pathway.

Post-menopausal women. Vyleesi's trials only enrolled premenopausal women, so the FDA approval is limited to that population. But the mechanism applies equally to post-menopausal women experiencing desire changes.

Broader sexual wellness. Some practitioners prescribe PT-141 for patients without a clinical diagnosis who want to enhance sexual experience. This is off-label use under the provider's clinical judgment.

PT-141 vs Vyleesi vs Viagra: Comparison

Frequently Asked Questions